Last Updated:
Searching
Create account to add to watchlist!

DA32 Life Science Tech Acquisition Corp. - DALS

  • Commons

    $9.85

    -0.40%

    DALS Vol: 0.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 203.4M
Average Volume: 13.8K
52W Range: $9.66 - $10.26
Weekly %: -0.40%
Monthly %: +0.10%
Inst Owners: 8

Info

Target: Searching
Days Since IPO: 123
Unit composition:
nan
Trust Size: 20000000.0M

Management

Our officers, directors and director nominees are as follows: Name Age Position Steve Kafka 51 Chief Executive Officer and Director Christopher Wolfe 41 Chief Financial Officer and Secretary Andrew ElBardissi 39 Director Nominee Keith Crandell 61 Director Nominee Mara Aspinall 58 Director Nominee Kevin Hrusovsky 60 Director Nominee Angela Lai 50 Director Nominee Nick Roelofs 63 Director Nominee Steve Kafka, Ph.D., has been our Chief Executive Officer since April 2021. Dr. Kafka is a Managing Partner of Section 32, where he focuses on investments in innovative companies operating at the confluence of life sciences and technology. Dr. Kafka has led the firm’s investments in companies including Thrive Earlier Detection Corp., Glympse Bio, Inc., Celsius Therapeutics, Inc., and C2i Genomics. Dr. Kafka is also an accomplished company-builder and strategic leader in molecular diagnostics and data: from April 2019 to January 2021 he was founding Chief Executive Officer and Executive Chairman of Thrive Earlier Detection Corp., a healthcare company advancing a breakthrough blood test for the earlier detection of multiple types of cancer that was acquired by EXACT Sciences Corporation (Nasdaq: EXAS) in January 2021; from June 2018 to October 2020 he was Executive Chairman of ArcherDx, Inc., an innovator in personalized cancer monitoring utilizing next generation sequencing that was acquired by Invitae Corporation (NYSE: NVTA) in October 2020; and from January 2013 to February 2018 he was President and Chief Operating Officer of Foundation Medicine, Inc., a pioneer in oncology precision medicine that was acquired by Roche in June 2018. Dr. Kafka is currently Chairman at Glympse Bio, Inc. and a director of ImmuneID, Inc., and was previously an independent director at Relay Therapeutics (Nasdaq: RLAY) from June 2018 to August 2019. Previously, Dr. Kafka held senior leadership roles with several therapeutic biotechnology companies including Millennium Pharmaceuticals, Inc., Infinity Pharmaceuticals, Inc. (Nasdaq: INFI), and Aileron Therapeutics (Nasdaq: ALRN). Dr. Kafka was also previously a Research Director at the leading technology research and consulting firm Forrester Research and was a Senior Engagement Manager at boutique strategy consultancy Strategic Decisions Group. Dr. Kafka holds a Ph.D. in political economy and government from Harvard University and an A.B. degree in economics and political science from Stanford University. Christopher Wolfe has been our Chief Financial Officer since April 2021. Mr. Wolfe has 20 years of experience in investing in healthcare and services businesses with a focus on complex and structured transactions. Mr. Wolfe has served as chief financial officer of previous Deerfield-sponsored SPACs, including DFB Healthcare Acquisitions Corp. until the consummation of its business combination in November 2019 with AdaptHealth Corp. (Nasdaq: AHCO), Deerfield Healthcare Technology Acquisitions Corp. until the consummation of its business combination in June 2021 with CareMax Inc. (Nasdaq: CMAX), and DFP Healthcare Acquisitions Corp. (Nasdaq: DFPH), which announced a business combination with The Oncology Institute in June 2021. Mr. Wolfe helped source, negotiate, structure and execute the business combination transactions with AdaptHealth Corp., CareMax Inc., and The Oncology Institute. From June 2003 to December 2017, Mr. Wolfe was a partner of Capital Z Partners Management, LLC, a middle-market private equity fund that has invested $3 billion in over 50 transactions since 1990, and worked in M&A at Credit Suisse First Boston. Mr. Wolfe graduated magna cum laude from Harvard College. Andrew ElBardissi, M.D., will serve on our board of directors following this offering. Dr. ElBardissi is a Partner on the structured products team at Deerfield Management, where he has been since January 2017, and focuses 121 Table of Contents on healthcare technology, including diagnostics and life sciences tools. At Deerfield Management, Dr. ElBardissi has led investments and serves as a member of the Boards of Directors of Sema4, Singular Genomics, Encodia, Inc., DNAMx, Inc., Epic Sciences, Acutus Medical Inc., Farapulse, Inc., Endologix LLC, Element Science, Inc., and InCarda Therapeutics, Inc., among others. Previously, Dr. ElBardissi was a principal at Longitude Capital from January 2014 to January 2017 and a banker in J.P. Morgan’s (NYSE: JPM) healthcare practice. Dr. ElBardissi holds an M.D. from the Mayo Clinic, an M.P.H. in Quantitative Methods from Harvard University, an M.B.A. from Harvard Business School and a B.S. with honors in Biology (Phi Beta Kappa) from the Schreyer Honors College at the Pennsylvania State University. He received his residency training in General Surgery at Harvard Medical School’s Brigham and Women’s Hospital and in Cardiothoracic Surgery at Stanford. Keith Crandell will serve on our board of directors following this offering. Mr. Crandell is a co-founder and has served as a Managing Director of ARCH Venture Partners since July 1994, where he focuses on life science tools, devices, and diagnostics. He currently serves on the Board of Directors of Quanterix Corporation (Nasdaq: QTRX), a publicly-traded company focusing on ultra-sensitive digital biomarker detection; Twist Bioscience (Nasdaq: TWST), a publicly-traded synthetic biology company whose silicon-based DNA writing platform offers broad application across the life science and biotherapeutics, and 908 Devices Inc. (Nasdaq: MASS), a publicly-traded company focused on bringing mass spectrometry to bio discovery and processing and field forensic applications. Mr. Crandell has played a key role in the formation and initial funding round of life science companies, including Quanterix Corporation, Twist Bioscience; and 908 Devices Inc., among others. Mr. Crandell is also a director of several private companies and serves on the Entrepreneurship Advisory Board at the Polsky Center for Entrepreneurship and Innovation of the University of Chicago Booth School of Business, the University of Chicago Pritzker School of Molecular Engineering Advisory Council, and on the Investment Advisory Board for the Partners Innovation Fund, a venture capital fund affiliated with Harvard Medical School Hospitals. Mr. Crandell has a B.S. degree in chemistry and mathematics from St. Lawrence University, an M.S. in chemistry from the University of Texas at Arlington, and an M.B.A. from the University of Chicago. Mara Aspinall will serve on our board of directors following this offering. Ms. Aspinall has been a Managing Director and Co-Founder of BlueStone Venture Partners, a venture fund investing in life sciences technology companies in the US Southwest, since 2017, and has been Managing Director of the Health Catalysts Group, a consulting firm dedicated to the growth of health information technology and diagnostics firms, since 2014. Ms. Aspinall previously served as Executive Chairman of GenePeeks from January 2015 to May 2018. She currently serves on the Board of Directors of Abcam plc since 2015, Allscripts (Nasdaq: MDRX) since 2017, Castle Biosciences (Nasdaq: CSTL) since 2015, OraSure (Nasdaq: OSUR) since 2017, and Blue Cross Blue Shield Arizona since 2015. She previously served on the Health and Human Services Secretary’s Advisory Committee on Genetics, Health and Society (SACGHS) in the Obama and Bush administrations. Ms. Aspinall was the President and CEO of Ventana Medical Systems, a billion-dollar division of The Roche Group (now Roche Tissue Diagnostics), from 2011 to 2014. Previously, she spent 13 years at Genzyme Corporation from 1997 to 2009 where she served as President of Genzyme Genetics and Genzyme Pharmaceuticals. She transformed Genzyme Genetics from a small specialized player to one of the leading laboratories in the country, prior to its sale to LabCorp for $925 million. Ms. Aspinall has a B.A. from Tufts University and an M.B.A. from Harvard Business School. Kevin Hrusovsky will serve on our board of directors following this offering. Mr. Hrusovsky has been Chairman and CEO of Quanterix (Nasdaq: QTRX), a company digitizing biomarker analysis to advance the science of precision health, since 2015. Prior to joining Quanterix, he was President of Life Sciences and Technologies at PerkinElmer (NYSE: PKI) from 2011 to 2013, CEO of Caliper Life Sciences (now PerkinElmer) from 2003 to 2011 and CEO of Zymark Corporation (now PerkinElmer) from 1996 to 2003. Previously, he served as President of FMC Corporation’s (NYSE: FMC) Pharmaceuticals division from 1992 to 1995 and as head of International Agricultural Products from 1995 to 1996 and held key management positions at E.I. DuPont de Nemours from 122 Table of Contents 1983 to 1992. Mr. Hrusovsky currently serves on the Board of Directors of BioreclamationIVT since 2016, and is Chairman of 908 Devices (Nasdaq: MASS) and has been on the board since 2013. He previously served on the Board of SeraCare from 2010 to 2012, Caliper Life Sciences from 2003 to 2011, Synap Dx (Nasdaq: SYNA) from 2013 to 2017, Cellaria from 2015 to 2019 and Xenogen from 2004 to 2006. Additionally, he serves on the Educational Board of the Massachusetts Biotechnology Council, the Advisory Committee for the Center for Biomedical Engineering at Brown University, the Association for Laboratory Automation, the Journal of Laboratory Automation Editorial Board, and the Strategy Committee of Boston Children’s Hospital. Mr. Hrusovsky has a B.S. in Mechanical Engineering from The Ohio State University and an M.B.A. from Ohio University. Angela Lai will serve on our board of directors following this offering. Ms. Lai is CEO of BetterOmics, a company she founded in 2019, building an AI data engineering platform for Life Science companies. Previously, she was the Chief Technology Officer at GRAIL, a company developing a blood-based diagnostic for early cancer detection, from 2018 to 2019 and held other roles since joining the company in 2016. Prior to her endeavors in the life science industry, she was a Vice President at Google (Nasdaq: GOOG) from 2004 to 2016, where she led the Product and Engineering teams that developed key Google products, including Search, Payments, and AdWords. Ms. Lai has a B.S.E. in Computer Engineering from the School of Engineering and Applied Sciences at the University of Pennsylvania, a B.S. in Economics concentrating in Finance from the Wharton School at the University of Pennsylvania, and a Master’s degree in Robotics from the School of Engineering and Applied Sciences at the University of Pennsylvania. Nick Roelofs, Ph.D., will serve on our board of directors following this offering. Dr. Roelofs has been an Advising Partner for Summa Equity, a Swedish private equity firm, since 2019, and an Industrial Advisor for Nordic Capital, a Swedish private equity firm, since 2014. He has been directly involved in four start-up companies and several multi-national corporations including Baxter Healthcare (NYSE: BAX) from 1989 to 1997, Applied Biosystems from 1997 to 2001, Stratagene from 2001 to 2004, Bio-Rad (NYSE: BIO) from 2004 to 2005, and Agilent Technologies Inc. (NYSE: A), where he served as the President of the Life Sciences Group at Agilent from 2009 to 2013. Dr. Roelofs currently serves on eight company Boards of Directors for a range of venture capital backed start-ups, larger private equity backed multinational companies and U.S. public companies, including Olink Holding AB (Nasdaq: OLK) since 2018. He also serves as an advisor to a range of governments and public, private equity, and venture capital investors. Dr. Roelofs has an M.S. in Organic Chemistry from Iowa State University and a Ph.D. in Organic Chemistry from the University of Nevada, Reno. Number and terms of office of officers and directors Our board of directors consists of seven members is divided into three classes with only one class of directors being elected in each year, and with each class (except for those directors appointed prior to our first annual meeting of stockholders) serving a three-year term. In accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following our listing on Nasdaq. The term of office of the first class of directors, consisting of [ ], will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of [ ], will expire at the second annual meeting of stockholders. The term of office of the third class of directors, consisting of [ ], will expire at the third annual meeting of stockholders. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint officers as it deems appropriate pursuant to our amended and restated certificate of incorporation. 123 Table of Contents Director independence Nasdaq listing standards require that a majority of our board of directors be independent within one year of our initial public offering. Our board of directors has determined that Mara Aspinall, Kevin Hrusovsky, Angela Lai and Nick Roelofs are “independent directors” as defined in Nasdaq listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Executive officer and director compensation None of our executive officers or directors have received any cash compensation for services rendered to us. Commencing on the date that our securities are first listed on Nasdaq through the earlier of consummation of our initial business combination and our liquidation, we will pay our sponsor $10,000 per month for office space, secretarial and administrative services provided to members of our management team. In addition, our sponsor, executive officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, executive officers or directors, or our or their affiliates. Any such payments prior to an initial business combination will be made from funds held outside the trust account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments and reimbursements, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to our sponsor, executive officers and directors, or any of their respective affiliates, prior to completion of our initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to stockholders, to the extent then known, in the proxy solicitation materials or tender offer materials furnished to our stockholders in connection with a proposed business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible for determining executive officer and director compensation. Any compensation to be paid to our executive officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our executive officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our executive officers and directors that provide for benefits upon termination of employment. 124 Table of Contents Committees of the board of directors Our board of directors will have two standing committees: an audit committee and a compensation committee. Subject to phase-in rules and a limited exception, the rules of Nasdaq and Rule 10A-3 of the Exchange Act require that the audit committee of a listed company be comprised solely of independent directors. Subject to phase-in rules and a limited exception, the rules of Nasdaq require that the compensation committee of a listed company be comprised solely of independent directors. Audit committee Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Ms. Aspinall, Mr. Hrusovsky and Dr. Roelofs will serve as members of our audit committee, and [ ] will chair the audit committee. All members of our audit committee are independent of and unaffiliated with our sponsor and our underwriters. Each member of the audit committee is financially literate and our board of directors has determined that [ ] qualifies as an “audit committee financial expert” as defined in applicable SEC rules and has accounting or related financial management expertise. We will adopt an audit committee charter, which will detail the principal functions of the audit committee, including: • assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent registered public accounting firm’s qualifications and independence, and (4) the performance of our internal audit function and independent registered public accounting firm; the appointment, compensation, retention, replacement, and oversight of the work of the independent registered public accounting firm and any other independent registered public accounting firm engaged by us; • pre-approving all audit and non-audit services to be provided by the independent registered public accounting firm or any other registered public accounting firm engaged by us, and establishing pre-approval policies and procedures; reviewing and discussing with the independent registered public accounting firm all relationships the auditors have with us in order to evaluate their continued independence; • setting clear policies for audit partner rotation in compliance with applicable laws and regulations; obtaining and reviewing a report, at least annually, from the independent registered public accounting firm describing (1) the independent registered public accountin

Holder Stats

1 0
% of Shares Held by All Insider 7.25%
% of Shares Held by Institutions 41.67%
% of Float Held by Institutions 44.93%
Number of Institutions Holding Shares 8

Mutual Fund Holders

Holder Shares Date Reported Value % Out
USAA Mutual Fund Tr-Science & Technology Fund 917818 2021-07-30 9178180 4.44
Brinker Capital Destinations Tr-Destinations Multi Strategy Alt Fd 743800 2021-08-30 7259488 3.5999999999999996
Hartford Healthcare Fund 610459 2021-07-30 6104590 2.96
iShares BlackRock Future Health ETF 3181 2021-09-29 31269 0.02

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-16 Wellington Management Group LLP 3,094,803 $30,420,000 0.0% 0 12.066%
2021-11-16 Millennium Management LLC 902,889 $8,880,000 0.0% 0 3.520%
2021-11-16 Moore Capital Management LP 750,000 $7,370,000 0.1% 0 2.924%
2021-11-16 Citadel Advisors LLC 611,917 $6,020,000 0.0% 0 2.386%
2021-11-15 Fortress Investment Group LLC 50,008 $490,000 0.0% 0 0.195%
2021-11-15 Point72 Hong Kong Ltd 12,767 $130,000 0.0% 0 0.050%
2021-11-15 Deerfield Management Company L.P. Series C 1,600,000 $15,730,000 0.3% 0 6.238%
2021-11-15 Pura Vida Investments LLC 200,000 $1,970,000 0.1% 0 0.780%
2021-11-15 Berkley W R Corp 157,016 $1,540,000 0.1% 0 0.612%
2021-11-15 Marshall Wace LLP 400,000 $3,930,000 0.0% 0 1.559%
2021-11-15 RA Capital Management L.P. 1,500,000 $14,750,000 0.2% 0 5.848%
2021-11-15 Glazer Capital LLC 21,990 $220,000 0.0% 0 0.086%
2021-11-12 Ghisallo Capital Management LLC 225,313 $2,220,000 0.1% 0 0.878%
2021-11-12 Arena Capital Advisors LLC CA 76,314 $750,000 0.1% 0 0.298%
2021-11-12 Sculptor Capital LP 60,040 $590,000 0.0% 0 0.234%
2021-11-12 Magnetar Financial LLC 930,047 $9,140,000 0.1% 0 3.626%
2021-11-10 Segantii Capital Management Ltd 100,000 $980,000 0.0% 0 0.390%
2021-11-09 BlackRock Inc. 1,500,000 $14,750,000 0.0% 0 5.848%
2021-11-09 Monashee Investment Management LLC 400,000 $3,930,000 0.7% 0 1.559%
2021-11-08 Toronto Dominion Bank 10,900 $110,000 0.0% 0 0.042%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q FORM 10-Q 2021-11-15 https://www.sec.gov/Archives/edgar/data/1863294/000119312521329827/d234904d10q.htm
SC 13G SEC SCHEDULE 13G 2021-08-10 https://www.sec.gov/Archives/edgar/data/1863294/000090221921000382/SEC13G_Filing.htm
SC 13D SC 13D 2021-08-10 https://www.sec.gov/Archives/edgar/data/1863294/000119312521240746/d120533dsc13d.htm
SC 13D SC 13D 2021-08-10 https://www.sec.gov/Archives/edgar/data/1863294/000119312521240730/d145050dsc13d.htm
SC 13D SC 13D 2021-08-10 https://www.sec.gov/Archives/edgar/data/1863294/000119312521240727/d146494dsc13d.htm
4 FORM 4 SUBMISSION 2021-08-09 https://www.sec.gov/Archives/edgar/data/1863294/000089924321032284/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2021-08-09 https://www.sec.gov/Archives/edgar/data/1863294/000089924321032276/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2021-08-09 https://www.sec.gov/Archives/edgar/data/1863294/000089924321032272/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2021-08-09 https://www.sec.gov/Archives/edgar/data/1863294/000089924321032269/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2021-08-09 https://www.sec.gov/Archives/edgar/data/1863294/000089924321032264/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2021-08-09 https://www.sec.gov/Archives/edgar/data/1863294/000089924321032222/xslF345X03/doc4.xml
SC 13G SC 13G 2021-08-09 https://www.sec.gov/Archives/edgar/data/1863294/000110465921102252/tm2124573d2_sc13g.htm
SC 13D SC 13D 2021-08-09 https://www.sec.gov/Archives/edgar/data/1863294/000119312521240641/d168550dsc13d.htm
SC 13G SEC SCHEDULE 13G 2021-08-09 https://www.sec.gov/Archives/edgar/data/1863294/000167885821000003/SEC13G_Filing.htm
8-K FORM 8-K 2021-08-05 https://www.sec.gov/Archives/edgar/data/1863294/000119312521237955/d194894d8k.htm
4 FORM 4 SUBMISSION 2021-08-03 https://www.sec.gov/Archives/edgar/data/1863294/000089924321031450/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2021-08-03 https://www.sec.gov/Archives/edgar/data/1863294/000089924321031427/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2021-08-03 https://www.sec.gov/Archives/edgar/data/1863294/000089924321031417/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2021-08-03 https://www.sec.gov/Archives/edgar/data/1863294/000089924321031411/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2021-08-03 https://www.sec.gov/Archives/edgar/data/1863294/000089924321031406/xslF345X03/doc4.xml
8-K FORM 8-K 2021-07-30 https://www.sec.gov/Archives/edgar/data/1863294/000119312521231358/d198820d8k.htm
424B4 424B4 2021-07-29 https://www.sec.gov/Archives/edgar/data/1863294/000119312521229185/d184855d424b4.htm
EFFECT 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/999999999521002938/xslEFFECTX01/primary_doc.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030234/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030233/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030231/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030230/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030193/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030192/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030191/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030190/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030187/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030183/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030184/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000089924321030182/xslF345X02/doc3.xml
CERT 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000135445721000849/8A_cert_DALS.pdf
8-A12B 8-A12B 2021-07-27 https://www.sec.gov/Archives/edgar/data/1863294/000119312521224949/d95282d8a12b.htm
CORRESP 2021-07-23 https://www.sec.gov/Archives/edgar/data/1863294/000119312521222996/filename1.htm
CORRESP 2021-07-23 https://www.sec.gov/Archives/edgar/data/1863294/000119312521222994/filename1.htm
CORRESP 2021-07-15 https://www.sec.gov/Archives/edgar/data/1863294/000119312521216409/filename1.htm
S-1/A S-1/A 2021-07-15 https://www.sec.gov/Archives/edgar/data/1863294/000119312521216405/d184855ds1a.htm
UPLOAD 2021-07-14 https://www.sec.gov/Archives/edgar/data/1863294/000000000021008684/filename1.pdf
S-1 S-1 2021-07-02 https://www.sec.gov/Archives/edgar/data/1863294/000119312521207738/d184855ds1.htm
CORRESP 2021-07-02 https://www.sec.gov/Archives/edgar/data/1863294/000119312521207737/filename1.htm
UPLOAD 2021-06-23 https://www.sec.gov/Archives/edgar/data/1863294/000000000021007722/filename1.pdf
DRS 2021-05-28 https://www.sec.gov/Archives/edgar/data/1863294/000095012321007435/filename1.htm